GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00447725 | Cervix | CC | mitotic cell cycle phase transition | 89/2311 | 424/18723 | 2.70e-07 | 1.12e-05 | 89 |
GO:00457876 | Cervix | CC | positive regulation of cell cycle | 66/2311 | 313/18723 | 7.78e-06 | 1.81e-04 | 66 |
GO:00073466 | Cervix | CC | regulation of mitotic cell cycle | 88/2311 | 457/18723 | 1.26e-05 | 2.60e-04 | 88 |
GO:19019903 | Cervix | CC | regulation of mitotic cell cycle phase transition | 63/2311 | 299/18723 | 1.27e-05 | 2.60e-04 | 63 |
GO:00459316 | Cervix | CC | positive regulation of mitotic cell cycle | 32/2311 | 121/18723 | 1.88e-05 | 3.47e-04 | 32 |
GO:19019922 | Cervix | CC | positive regulation of mitotic cell cycle phase transition | 26/2311 | 93/18723 | 3.97e-05 | 6.18e-04 | 26 |
GO:00017018 | Cervix | CC | in utero embryonic development | 71/2311 | 367/18723 | 7.21e-05 | 1.00e-03 | 71 |
GO:00900685 | Cervix | CC | positive regulation of cell cycle process | 50/2311 | 236/18723 | 8.25e-05 | 1.11e-03 | 50 |
GO:19019873 | Cervix | CC | regulation of cell cycle phase transition | 74/2311 | 390/18723 | 9.80e-05 | 1.27e-03 | 74 |
GO:19019892 | Cervix | CC | positive regulation of cell cycle phase transition | 28/2311 | 115/18723 | 2.82e-04 | 3.07e-03 | 28 |
GO:1902751 | Cervix | CC | positive regulation of cell cycle G2/M phase transition | 11/2311 | 30/18723 | 5.71e-04 | 5.45e-03 | 11 |
GO:0010971 | Cervix | CC | positive regulation of G2/M transition of mitotic cell cycle | 10/2311 | 27/18723 | 9.25e-04 | 7.84e-03 | 10 |
GO:00448392 | Cervix | CC | cell cycle G2/M phase transition | 31/2311 | 148/18723 | 2.07e-03 | 1.51e-02 | 31 |
GO:00000862 | Cervix | CC | G2/M transition of mitotic cell cycle | 29/2311 | 137/18723 | 2.40e-03 | 1.70e-02 | 29 |
GO:00482851 | Cervix | CC | organelle fission | 78/2311 | 488/18723 | 9.70e-03 | 4.79e-02 | 78 |
GO:0001701 | Colorectum | AD | in utero embryonic development | 110/3918 | 367/18723 | 2.36e-05 | 4.62e-04 | 110 |
GO:0007346 | Colorectum | AD | regulation of mitotic cell cycle | 119/3918 | 457/18723 | 4.60e-03 | 3.14e-02 | 119 |
GO:0045787 | Colorectum | AD | positive regulation of cell cycle | 85/3918 | 313/18723 | 4.76e-03 | 3.22e-02 | 85 |
GO:0045931 | Colorectum | AD | positive regulation of mitotic cell cycle | 37/3918 | 121/18723 | 7.88e-03 | 4.73e-02 | 37 |
GO:00017011 | Colorectum | SER | in utero embryonic development | 77/2897 | 367/18723 | 2.77e-03 | 2.48e-02 | 77 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAD51 | SNV | Missense_Mutation | | c.656T>G | p.Leu219Arg | p.L219R | Q06609 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-BH-A0HW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
RAD51 | SNV | Missense_Mutation | | c.448N>A | p.Asp150Asn | p.D150N | Q06609 | protein_coding | tolerated(0.14) | benign(0.117) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RAD51 | SNV | Missense_Mutation | novel | c.146N>C | p.Val49Ala | p.V49A | Q06609 | protein_coding | tolerated(0.06) | benign(0.082) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAD51 | SNV | Missense_Mutation | novel | c.87N>T | p.Glu29Asp | p.E29D | Q06609 | protein_coding | deleterious(0.04) | benign(0.021) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAD51 | SNV | Missense_Mutation | | c.584C>T | p.Ala195Val | p.A195V | Q06609 | protein_coding | deleterious(0.02) | possibly_damaging(0.483) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
RAD51 | SNV | Missense_Mutation | novel | c.922N>T | p.Gly308Trp | p.G308W | Q06609 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAD51 | SNV | Missense_Mutation | | c.629N>T | p.Ala210Val | p.A210V | Q06609 | protein_coding | deleterious(0.02) | possibly_damaging(0.703) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAD51 | SNV | Missense_Mutation | novel | c.949G>A | p.Asp317Asn | p.D317N | Q06609 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
RAD51 | SNV | Missense_Mutation | novel | c.52N>A | p.Glu18Lys | p.E18K | Q06609 | protein_coding | tolerated(0.08) | benign(0.014) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAD51 | SNV | Missense_Mutation | | c.171N>T | p.Lys57Asn | p.K57N | Q06609 | protein_coding | deleterious(0) | possibly_damaging(0.726) | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |